The Asia-Pacific clinical trials support services market is anticipated to record an 8.21% CAGR over the estimation period of 2022 to 2030, generating a revenue of $10461.65 million by 2030.

ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET FORECAST 2022-2030

Asia-Pacific Clinical Trials Support Services Market by Phase (Phase I, Phase II, Phase III, Phase IV) Market by Sponsor (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, Other Sponsors) Market by Service (Clinical Trial Site Management, Administrative Services, Patient Recruitment Management, Regulatory Services, Data Management, Other Services) by Geography

Request free sample

Report Summary

Asia-Pacific region is considered to have the largest populated region and especially Asia. Therefore, this adds an advantage to the clinical trial processes as the researchers can access a large population of patients. In clinical trials, researchers get high-quality data at a very low cost compared to the United States and Europe, which is an advantage to the clinical trial process. Also, the cost of conducting a clinical trial in the Asia-Pacific region is significantly less than in the United States and western Europe.

To know more about this report, request a free sample copy

The Asia-Pacific clinical trials support services market growth analysis includes the evaluation of Thailand, Taiwan, China, Singapore, South Korea, India, Australia & New Zealand, Japan, and Rest of Asia-Pacific. China is an opportunity-based country for clinical trials due to its large population available for clinical trials. The government regulations are also supportive in terms of conducting them.

Further, China focuses on increasing the number of clinical trials conducted annually. Since the segment is developing in the country, the quality of the clinical trials has also made considerable progress. However, the trials need more transparency and quality control improvement. Also, various pharmaceutical companies have recently increased their focus on China with increasing government support, aiming to make China a more desirable country for clinical trials.

Furthermore, in Japan, the pharmaceutical companies or the CROs prefer to conduct clinical trials because the Japanese regulatory frameworks have now started focusing on aligning drug approval timelines with the United States and Europe. Earlier, medicines in Japan used to be available to patients almost after five to ten years after their counterparts in the United States or Europe. With the improvement in the regulatory frameworks’ guidelines, the bar for conducting clinical trials in Japan is now moving upwards.

The Asia-Pacific clinical trials support services market is segmented into sponsor, phase, and service. Market by phase includes phase I, phase II, phase III, and phase IV.

Phase I clinical trial is the first step toward the clinical trials, which ensures that the trial is safe for humans and examines how and where the drug or the vaccine is distributed in the body. Only a small group of healthy people take voluntary participation. The first few people in the study get a very low treatment dose and are watched very closely. If only minor side effects exist, the next few participants get a higher dose. This process continues until doctors find a dose most likely to work while having acceptable side effects.

After performing a phase I clinical trial and getting approval for the phase II clinical trial, the trial’s main goal is to monitor how much dosage would be preferable and effective in treating the diseases. In phase II clinical trials, many people with the disease voluntarily participate so fewer common side effects may be seen. The sponsors can conduct the trial according to them. Usually, participants or patients are assigned to different treatment groups, where the group receives different doses and treatment delivery.

Some top players operating in the Asia-Pacific clinical trials support services market are WuXi AppTec, CMIC Group, and EPS Corporation.

WuXi AppTec is a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical and healthcare industry. Through its business models, WuXi AppTec’s end-to-end integrated services include biology discovery, clinical research services & preclinical testing, and gene & cell therapies, helping customers to improve their productivity with the help of advanced healthcare products efficiently and cost-effectively. It operates in Asia, North America, Europe, and the Middle East. WuXi AppTec was founded in 2000 and is headquartered in Shanghai, China.

WuXi Advanced Therapies offer analytical testing services to characterize vaccines, complex biologies, and advanced therapies.

Report Synopsis

Report Scope	Details
Market Forecast Years	2022-2030
Base Year	2021
Market Historical Years	2018-2021
Forecast Units	Revenue ($ Million)
Segments Analyzed	Phase, Sponsor, and Service
Countries Analyzed	China, Japan, India, South Korea, Taiwan, Singapore, Thailand, Australia & New Zealand, and Rest of Asia-Pacific
Companies Analyzed	Advanced Clinical, Alcura, Charles River Laboratories Inc, Clinipace, CTI Clinical Trial and Consulting Services Inc, ICON PLC, IQVIA, KCR, Labcorp Drug Development, Medpace, Parexel, PSI CRO, Syneos Health, Worldwide Clinical Trials, WuXi AppTec

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
MARKET DYNAMICS
- KEY DRIVERS
  - RISING PREVALENCE OF CHRONIC DISEASE & VIRUS OUTBREAKS
  - BENEFITS OF CLINICAL TRIAL SUPPORT SERVICES
- KEY RESTRAINTS
  - AVAILABILITY OF OPEN-SOURCE/FREEWARE SOFTWARE
  - STRINGENT REGULATIONS

KEY ANALYTICS
- IMPACT OF COVID-19 ON CLINICAL TRIALS SUPPORT SERVICES MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
  - BUYERS POWER
  - SUPPLIERS POWER
  - SUBSTITUTION
  - NEW ENTRANTS
  - INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- VALUE CHAIN ANALYSIS
- KEY BUYING CRITERIA
  - PERFORMANCE
  - EASE OF USE
  - SECURITY
  - COST-EFFECTIVENESS
- REGULATORY FRAMEWORK
MARKET BY PHASE
- PHASE I
- PHASE II
- PHASE III
- PHASE IV
MARKET BY SPONSOR
- PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- MEDICAL DEVICE COMPANIES
- OTHER SPONSORS
MARKET BY SERVICE
- CLINICAL TRIAL SITE MANAGEMENT
- ADMINISTRATIVE SERVICES
- PATIENT RECRUITMENT MANAGEMENT
  - PATIENT RECRUITMENT & REGISTRY SERVICES
  - PATIENT RETENTION
  - OTHER PATIENT RECRUITMENT MANAGEMENT
- REGULATORY SERVICES
- DATA MANAGEMENT
- OTHER SERVICES
GEOGRAPHICAL ANALYSIS
- ASIA-PACIFIC
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - CHINA
    - JAPAN
    - INDIA
    - SOUTH KOREA
    - TAIWAN
    - SINGAPORE
    - THAILAND
    - AUSTRALIA & NEW ZEALAND
    - REST OF ASIA-PACIFIC

COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
  - MERGERS & ACQUISITIONS
  - PRODUCT LAUNCHES & DEVELOPMENTS
  - PARTNERSHIPS & AGREEMENTS
  - BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
  - ADVANCED CLINICAL
  - ALCURA
  - CHARLES RIVER LABORATORIES INC
  - CLINIPACE
  - CTI CLINICAL TRIAL AND CONSULTING SERVICES INC
  - ICON PLC
  - IQVIA
  - KCR
  - LABCORP DRUG DEVELOPMENT
  - MEDPACE
  - PAREXEL
  - PSI CRO
  - SYNEOS HEALTH
  - WORLDWIDE CLINICAL TRIALS
  - WUXI APPTEC

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – CLINICAL TRIALS SUPPORT SERVICES

TABLE 2: LIST OF PANDEMIC OUTBREAKS

TABLE 3: LIST OF OPEN-SOURCE SOFTWARE

TABLE 4: LIST OF PARTNERSHIPS

TABLE 5: LAUNCH OF MEDICAL DRUGS

TABLE 6: PROMISING ACQUISITIONS IN THE INDUSTRY

TABLE 7: REGULATORY FRAMEWORK

TABLE 8: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SPONSOR, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 11: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SPONSOR, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 12: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 13: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 14: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PATIENT RECRUITMENT MANAGEMENT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 15: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PATIENT RECRUITMENT MANAGEMENT, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 16: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 17: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 18: LEADING PLAYERS OPERATING IN ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET

TABLE 19: LIST OF MERGERS & ACQUISITIONS

TABLE 20: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 21: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 22: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: VALUE CHAIN ANALYSIS

FIGURE 6: KEY BUYING CRITERIA

FIGURE 7: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, GROWTH POTENTIAL, BY PHASE, IN 2021

FIGURE 8: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE I, 2022-2030 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE II, 2022-2030 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE III, 2022-2030 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE IV, 2022-2030 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, GROWTH POTENTIAL, BY SPONSOR, IN 2021

FIGURE 13: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY MEDICAL DEVICE COMPANIES, 2022-2030 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY OTHER SPONSORS, 2022-2030 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021

FIGURE 17: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY CLINICAL TRIAL SITE MANAGEMENT, 2022-2030 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY ADMINISTRATIVE SERVICES, 2022-2030 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PATIENT RECRUITMENT MANAGEMENT, 2022-2030 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, GROWTH POTENTIAL, BY PATIENT RECRUITMENT MANAGEMENT, IN 2021

FIGURE 21: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PATIENT RECRUITMENT & REGISTRY SERVICES, 2022-2030 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PATIENT RETENTION, 2022-2030 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY OTHER PATIENT RECRUITMENT MANAGEMENT, 2022-2030 (IN $ MILLION)

FIGURE 24: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY REGULATORY SERVICES, 2022-2030 (IN $ MILLION)

FIGURE 25: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY DATA MANAGEMENT, 2022-2030 (IN $ MILLION)

FIGURE 26: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, BY OTHER SERVICES, 2022-2030 (IN $ MILLION)

FIGURE 27: ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 28: CHINA CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

FIGURE 29: JAPAN CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

FIGURE 30: INDIA CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

FIGURE 31: SOUTH KOREA CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

FIGURE 32: TAIWAN CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

FIGURE 33: SINGAPORE CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

FIGURE 34: THAILAND CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

FIGURE 35: AUSTRALIA & NEW ZEALAND CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: REST OF ASIA-PACIFIC CLINICAL TRIALS SUPPORT SERVICES MARKET, 2022-2030 (IN $ MILLION)

Segmentation

GEOGRAPHICAL ANALYSIS
- ASIA-PACIFIC
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - CHINA
    - JAPAN
    - INDIA
    - SOUTH KOREA
    - TAIWAN
    - SINGAPORE
    - THAILAND
    - AUSTRALIA & NEW ZEALAND
    - REST OF ASIA-PACIFIC

MARKET BY PHASE
- PHASE I
- PHASE II
- PHASE III
- PHASE IV
MARKET BY SPONSOR
- PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- MEDICAL DEVICE COMPANIES
- OTHER SPONSORS
MARKET BY SERVICE
- CLINICAL TRIAL SITE MANAGEMENT
- ADMINISTRATIVE SERVICES
- PATIENT RECRUITMENT MANAGEMENT
  - PATIENT RECRUITMENT & REGISTRY SERVICES
  - PATIENT RETENTION
  - OTHER PATIENT RECRUITMENT MANAGEMENT
- REGULATORY SERVICES
- DATA MANAGEMENT
- OTHER SERVICES